

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936

REMARKS

The Claim Amendments

Applicants have amended claim 1 to delete recitation of non-elected subject matter. Applicants have amended claims 26 and 27 to improve their form. None of these amendments adds new subject matter. Their entry is requested.

Applicants reserve the right to pursue the canceled subject matter in this application or in future continuing or divisional applications.

The Response

The Restriction Requirement

The Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

- I. Claims 1-17 (in part), 18, 19-22 (in part), 23 and 24 (in part), drawn to benzomorpholines and benzo-1,3-oxazines;
- II. Claims 1-17 (in part), 19-22 (in part), 23 and 24 (in part), drawn to quinoxalines;
- III. Claim 25, drawn to a complex composition; and
- IV. Claims 26-29, drawn to a method of use.

Applicants elect Group I without traverse.


This election is made expressly without waiver of applicants' rights to continue to prosecute and to obtain claims to the non-elected subject matter either in this application or in other applications claiming benefit herefrom.

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936

Conclusion

Applicants request that the Examiner enter the above amendments, consider the accompanying arguments, and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at his convenience.

Respectfully submitted,


Karen E. Brown
Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483